Compare ASTC & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | BRTX |
|---|---|---|
| Founded | 1984 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 4.9M |
| IPO Year | 2020 | 2015 |
| Metric | ASTC | BRTX |
|---|---|---|
| Price | $2.43 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 6.2M |
| Earning Date | 02-13-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | 66.08 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.25 | $0.19 |
| 52 Week High | $8.01 | $2.10 |
| Indicator | ASTC | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.52 | 36.14 |
| Support Level | $2.25 | $0.19 |
| Resistance Level | $2.92 | $0.30 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 38.19 | 63.91 |
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.